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Abstract
Background: We investigated the prevalence of microalbuminuria and its association with the metabolic
syndrome and its components in a Chinese population.
Methods: The study subjects were recruited from a newly established residential area in the suburb of Shanghai.
We measured anthropometry, blood pressure (BP), fasting plasma glucose, and serum lipids, and collected spot
urine samples for the determination of albumin-creatinine ratio. We defined microalbuminuria as a urinary albumin-
to-creatinine ratio of 30 to 299 mg/g. The metabolic syndrome was defined according to the International
Diabetes Federation criteria.
Results: The 1079 participants included 410 (38.0%) hypertensive patients, and 66 (6.1%) diabetic patients. The
prevalence of microalbuminuria (4.3%) was 3.2 times higher in 167 patients with the metabolic syndrome than 912
subjects without the metabolic syndrome (12.0% vs. 2.9%, P < 0.0001). In multiple regression adjusted for sex, age,
body mass index, current smoking, alcohol intake and the use of antihypertensive drugs, and mutually adjusted for
the components, microalbuminuria was significantly associated with diastolic BP (odds ratio 1.74 for +10 mmHg;
95% confidence interval [CI] 1.10-2.76; P = 0.02) and fasting plasma glucose (1.18; 95% CI 1.01-1.41; P = 0.04), but
not with waist circumference, systolic BP, or serum HDL cholesterol and triglycerides (P > 0.10).
Conclusions: Microalbuminuria is common in the Chinese population, and much more prevalent in the presence
of the metabolic syndrome, mainly attributable to elevated diastolic BP and plasma glucose.
Background
Micoralbuminuria is an early marker of chronic kidney
disease (CKD) [1] and vascular dysfunction [2], and is
associated with a higher risk of renal function loss [1],
cardiovascular events [1,3], and all-cause mortality [3].
Microalbuminuria is relatively common in patients with
metabolic disorders, such as type 2 diabetes mellitus [4],
and has been incorporated into the definition of the
metabolic syndrome of the World Health Organization
[5]. However, whether microalbuminuria should be an
essential component of the metabolic syndrome remains
controversial. Indeed, the Adult Treatment Panel III cri-
teria (ATP III) [6], the American Heart Association cri-
teria [7], and the recent harmonized international
criteria [8] for the definition of the metabolic syndrome
included blood pressure, waist circumference, fasting
plasma glucose, serum triglycerides, and high-density
lipoprotein (HDL) cholesterol, but excluded microalbu-
minuria [9].
Nonetheless, several recent studies investigated the
relationship of microalbuminuria with the metabolic
syndrome and its components [10-14]. In the Third
National Health and Nutrition Examination Survey
(NHANES III), microalbuminuria was associated with
the metabolic syndrome, and mainly with the fasting
plasma glucose and blood pressure components [10].
The authors therefore propos e dt h a tm i c r o a l b u m i n u r i a
should become a component of the metabolic syndrome
[10]. Several studies in Eastern Asians confirmed the
association between microalbuminuria and the meta-
bolic syndrome, but produced inconsistent results on
the association between microalbuminuria and the
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performed the present cross-sectional analysis on the
association of microalbuminuria with the metabolic syn-
drome and its components in a Chinese general popula-
tion sample.
Methods
Study population
The present cross-sectional analysis was based on the
recent follow-up data of an ongoing longitudinal popu-
lation study on multiple cardiovascular risk factors in
Shanghai. The Ethics Committee of Ruijin Hospital,
Shanghai Jiaotong University School of Medicine
approved the study protocol. All subjects gave written
informed consent. The study subjects were recruited
from a newly established residential area in the suburb
of Shanghai, 30 kilometers from the city centre. Most
residents were immigrants from the nearby villages
since 2003, and previously doing farming or other agri-
cultural work. In the period from 2004 to 2006, we
invited all residents at least 12 years of age to take part.
Of the 2275 invited, 1700 (74.7%) participated in the
study.
At the time of the follow-up study in 2009, 1630 of
the 1700 subjects were still alive, 1192 (73.1%) partici-
pated in the follow-up examinations. We excluded 98
subjects, because they did not have blood (n = 22) or
spot urine sampling (n = 58), or anthropometric mea-
surements (n = 18). For the purpose of the present
study on microalbuminuria, we also excluded 15 sub-
jects with macroalbuminuria (urinary albumin-to-creati-
nine ratio ≥ 300 mg/g). Thus, the total number of
subjects included in the present analysis was 1079.
Filed work
One experienced physician measured each participant’s
b l o o dp r e s s u r ef i v et i m e sc o n s e c u t i v e l yb ym e r c u r y
sphygmomanometry, after the subjects had rested for at
least 5 minutes in the sitting position. These five blood
pressure readings were averaged for analysis. The same
observer also administered a standardized questionnaire
to collect information on medical history, smoking
habits, alcohol consumption and the use of medications.
Hypertension was defined as a sitting blood pressure of
at least 140 mmHg systolic or 90 mmHg diastolic, or as
the use of antihypertensive drugs. One trained techni-
cian performed anthropometric measurements, includ-
ing body height, body weight, and waist and hip
circumferences. Waist circumference was measured at
the smallest circumference between the ribs and iliac
crest, and hip circumference at maximum circumference
between the iliac crest and crotch to the nearest 0.1 cm.
Venous blood samples were drawn after overnight
fasting for the measurement of plasma glucose
concentration and for measurements of serum concen-
trations of total and HDL cholesterol, and triglycerides.
Diabetes mellitus was defined as a plasma glucose of at
least 7.0 mmol/L fasting or 11.1 mmol/L at any time, or
as the use of antidiabetic agents [5]. Fresh spot urine
samples were collected for the measurement of urinary
albumin and creatine, using immunoturbidimetry and
enzymatic methods, respectively. Urinary albumin excre-
tion was expressed as the albumin-to-creatinine ratio
(mg/g).
Definition of microalbuminuria and the metabolic
syndrome
We defined microalbuminuria as a urinary albumin-to-
creatinine ratio of 30 to 299 mg/g [5], and the metabolic
syndrome according to the IDF criteria [8]. The meta-
bolic syndrome could be diagnosed, if in the presence of
central obesity (waist circumference ≥ 90 cm for men
and ≥ 80 cm for women), plus any two of the following
four factors: 1) serum triglycerides ≥150 mg/dL
(1.7 mmol/L); 2) serum HDL cholesterol <40 mg/dL
(1 mmol/L) in men and <50 mg/dL (1.29 mmol/L) in
women; 3) blood pressure ≥130/85 mm Hg or the use
of antihypertensive drugs; and 4) fasting plasma glucose
≥100 mg/dL (5.6 mmol/L) or diabetes mellitus.
Statistical methods
For database management and statistical analysis, we
used SAS software (version 9.13, SAS Institute, Cary,
NC). Means and proportions were compared with the
normal z-test and Fisher’s exact test, respectively. Con-
tinuous measurements with a skewed distribution were
normalized by logarithmic transformation and repre-
sented by geometric mean and 95% CI. We performed
multiple logistic regression analyses to study the associa-
tion of microalbuminuria with the metabolic syndrome
and its components, while controlling for covariates
including sex, age, body mass index, current smoking,
alcohol intake and the use of antihypertensive drugs. In
further regression analyses, the metabolic syndrome
components were also mutually adjusted.
Results
1079 participants included 412 (38.2%) men and 410
(38.0%) hypertensive patients, of whom 331 (30.7%) took
antihypertensive drugs. Men and women had similar
systolic blood pressure (mean ± SD; 125.1 ± 18.7
mmHg), pulse rate (68.5 ± 8.4 beats/minute), fasting
plasma glucose (4.55 ± 1.34 mmol/L), serum total cho-
lesterol (4.74 ± 0.90 mmol/L), and prevalence of dia-
betes mellitus (6.1%, Table 1). Men, compared with
women, were slightly older (+2 years, P =0 . 0 1 ) ,
had a significantly (P ≤ 0.05) greater body mass
index (+0.5 kg/m
2), higher diastolic blood pressure
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L), and reported higher (P < 0.0001) proportions of cur-
rent smoking (47.8% vs. 0.5%) and alcohol intake (35.4%
vs.1 . 2 % ) .O v e r a l l ,2 0( 1 . 9 % )s u b j e c t sr e p o r t e dah i s t o r y
of stroke, and 1 (0.1%) had coronary artery disease.
Men and women had similar prevalence of microalbu-
minuria (3.4% vs.4.8%; P = 0.26) and the metabolic syn-
drome (14.6% vs.16.0%; P = 0.52). The prevalence of
microalbuminuria was higher with increasing number of
the metabolic syndrome components (Figure 1). Indeed,
the prevalence of microalbuminuria was 1.4% in subjects
without any metabolic syndrome components, and
increased to 3.6% in subjects with at least 1 metabolic
component but not diagnosed as the metabolic syn-
drome, and to 12.0% in subjects with the metabolic syn-
drome (P < 0.0001 for trend).
In unadjusted continuous analyses, microalbuminuria
was significantly (P < 0.01) associated with all the meta-
bolic syndrome components, except serum HDL choles-
terol (P = 0.59, Table 2). After adjustment for sex, age,
body mass index, current smoking, alcohol intake and
the use of antihypertensive drugs, the association
remained statistically significant (P < 0.01) for systolic
and diastolic blood pressure, and fasting plasma glucose.
However, after mutual adjustment for the components
of the metabolic syndrome, microalbuminuria was only
significantly associated with diastolic blood pressure
(odds ratio 1.74 for each 10 mmHg increase; 95% confi-
dence interval [CI] 1.10-2.76; P = 0.02) and fasting
plasma glucose (1.18 for each 1 mmol/L increase; 95%
CI 1.01-1.41; P = 0.04).
The categorical analysis was confirmatory (Table 3). In
fully adjusted analyses, the risk of microalbuminuria was
116% higher in patients with the blood pressure compo-
nent (systolic/diastolic blood pressure ≥130/85 mmHg,
P = 0.04), mainly because of elevated diastolic blood
pressure (odds ratio 2.25; 95% CI 1.09-4.65; P =0 . 0 3 ) ,
and was 157% higher in patients with elevated fasting
plasma glucose (P = 0.007).
After exclusion of 331 users of antihypertensive drugs,
we performed sensitivity analysis in 748 subjects not tak-
ing antihypertensive drugs (Table 4). The number of sub-
jects with microalbuminuria and the metabolic syndrome
decreased substantially from 46 to 24 and from 167 to 64,
respectively. Nonetheless, with similar adjustments applied
as above, microalbuminuria was strongly associated with
the metabolic syndrome (odds ratio 5.13, P = 0.001).
Table 1 Characteristics of the study population
Characteristic Men (n =
412)
Women (n =
667)
P
value
Demography
Age, years 57.0 ± 12.7 55.0 ± 12.9 0.01
Body mass index, kg/m
2 24.2 ± 3.5 23.7 ± 3.2 0.02
Waist-to-hip ratio 0.89 ± 0.06 0.86 ± 0.32 0.04
Blood pressure, mm Hg
Systolic 125.9 ± 17.5 124.7 ± 19.4 0.28
Diastolic 78.8 ± 9.6 75.4 ± 9.1 <0.0001
Pulse rate, beats/minute 68.1 ± 8.9 68.7 ± 8.0 0.29
Take antihypertensive drugs, n
(%)
139 (33.8) 192 (28.8) 0.09
Hypertension, n (%)
a 179 (43.6) 231 (34.7) 0.004
Diabetes mellitus, n (%)
a 28 (6.8) 38 (5.7) 0.41
Biochemical measurements
Plasma fasting glucose,
mmol/L
4.50 ± 1.55 4.57 ± 1.19 0.42
Serum total cholesterol,
mmol/L
4.73 ± 0.87 4.74 ± 0.91 0.90
Serum HDL cholesterol,
mmol/L
1.62 ± 0.45 1.81 ± 0.41 <0.0001
Serum triglycerides,
mmol/L
1.53 (1.44-
1.63)
1.27 (1.22-1.33) <0.0001
Microalbuminuria, n (%)
a 14 (3.4) 32 (4.8) 0.26
Metabolic syndrome, n (%)
a 60 (14.6) 107 (16.0) 0.52
Values are mean ± SD, geometric means (95% confidence interval), or the
numbers of subjects (%).
HDL, high density lipoprotein.
aFor definitions of hypertension, diabetes mellitus, microalbuminuria and the
metabolic syndrome, see Methods.
Figure 1 The prevalence of microalbuminuria by number of
the metabolic syndrome components subjects in men (closed
circles) and women (open circles) separately. On the horizontal
axis, 0 and ≥1 indicate subjects without any metabolic syndrome
components and those with at least 1 component but not
diagnosed as the metabolic syndrome, respectively. The number of
subjects per subgroup is given at the bottom, and those with
microalbuminuria alongside the symbols. P < 0.0001 for trend in
men and women combined.
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In our population-based study, we found that microalbu-
minuria was common in the Chinese population (4.3%)
in general and much more prevalent in persons with the
metabolic syndrome (12.0%) in particular. Among the 5
commonly considered components of the metabolic
syndrome, blood pressure and plasma glucose were the
major determinants of microalbuminuria.
Although we used lower sex-specific cut-off limits
to define microalbuminuria, the prevalence of micro-
albuminuria in our study population was slightly
lower than several previous population studies in Chi-
nese [11,13,14], Japanese [12], or US Americans [10],
in which the similar urinary albumin-to-creatinine
ratio technique was used in the assessment of micro-
albuminuria. Indeed, the prevalence of microalbumi-
n u r i aw a s6 . 7 %i n3 5 3 2C h i n e s e( m e a na g e5 0y e a r s )
living in the urban area of Shanghai [11], 8.8% in
2985 Chinese (mean age 44 years) living in a city 200
km south of Shanghai [14], 11.5% in 2311 Chinese
living in Taiwan (mean age 57 years) [13], 13.7% in
2321 Japanese (mean age 60 years) [12], and 6.4% in
5659 participants of the NHANES study (20-80 years)
[10]. The discrepancy in the prevalence of microalbu-
minuria across these populations might be attributa-
ble to the differences in the characteristics of study
participants, such as age and cardiovascular risk
factors.
Our finding on the association between microalbumi-
nuria and the metabolic syndrome is in line with the
results of the recently published studies [10-14]. The
prevalence of microalbuminuria was consistently higher
(P < 0.0001 for all) in persons with the metabolic syn-
drome than those without in Chinese (20.3% vs.2 . 0 % )
[14], Japanese (20.8% vs. 12.2%) [12], and US Americans
(13.7% vs. 4.8) [10]. With regard to the association with
specific metabolic syndrome components, 3 previous
studies [10-12] and our research produced similar
results. In 3532 Chinese, the risk of microalbuminuria
was significantly associated with high blood pressure
(odds ratio 2.15; P < 0.001) and hyperglycemia (odds
ratio 1.64; P = 0.01), but not with other components of
the metabolic syndrome [11]. In 2321 Japanese, microal-
buminuria was significantly associated with elevated
blood pressure (odds ratio 2.37; P <0 . 0 0 1 )a n dh y p e r -
glycemia (odds ratio 2.64; P < 0.001), weakly with cen-
tral obesity (odds ratio 1.31; P = 0.04), but not with
other components of the metabolic syndrome [12]. In
the NHANES study, microalbuminuria was associated
with high blood pressure and hyperglycemia in men
(odds ratio 2.51; P < 0.001 for both) as well as women
(odds ratio 3.34; P <0 . 0 0 1a n d2 . 2 4 ;P = 0.0047,
Table 2 Association of microalbuminuria with the metabolic syndrome components as continuous variables
The metabolic syndrome component Unadjusted Adjusted Model 1
a Adjusted Model 2
b
Odds ratio (95% CI) P value Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Waist circumference, +10 cm 1.64 (1.19-2.27) 0.003 1.43 (0.78-2.64) 0.25 1.30 (0.69-2.45) 0.42
Systolic blood pressure, +10 mm Hg 1.35 (1.17-1.55) <0.0001 1.32 (1.11-1.56) 0.002 1.08 (0.85-1.37) 0.55
Diastolic blood pressure, +10 mm Hg 1.90 (1.41-2.50) <0.0001 1.97 (1.41-2.76) <0.0001 1.74 (1.10-2.76) 0.02
Fasting plasma glucose, mmol/L 1.24 (1.08-1.42) 0.003 1.22 (1.05-1.42) 0.008 1.18 (1.01-1.41) 0.04
Serum triglycerides, mmol/L 1.10 (1.01-1.22) 0.04 1.09 (0.98-1.21) 0.12 1.03 (0.91-1.17) 0.63
Serum HDL cholesterol, mmol/L 0.83 (0.41-1.66) 0.59 0.94 (0.43-2.04) 0.87 1.30 (0.58-2.96) 0.53
CI, confidence interval; HDL, high density lipoprotein.
aAdjusted for sex, age, body mass index, current smoking, alcoholic intake and use of antihypertensive drugs.
bAdditionally adjusted for the other components of the metabolic syndrome.
Table 3 Association of microalbuminuria with the metabolic syndrome components as dichotomized variables
The metabolic syndrome
component
Number (Prevalence,
%)
Unadjusted Adjusted Model 1
a Adjusted Model 2
b
Odds ratio (95%
CI)
P
value
Odds ratio (95%
CI)
P
value
Odds ratio (95%
CI)
P
value
Central obesity 422 (39.1) 3.38 (1.80-6.34) 0.0001 2.52 (1.09-5.83) 0.03 2.24 (0.96-5.24) 0.06
Elevated blood pressure 522 (48.4) 3.16 (1.62-6.18) 0.0007 2.85 (1.22-6.67) 0.02 2.16 (1.01-4.63) 0.04
Elevated fasting plasma glucose 126 (11.7) 3.53 (1.83-6.81) 0.0002 3.03 (1.55-5.94) 0.001 2.57 (1.29-5.11) 0.007
Elevated serum triglycerides 356 (33.0) 2.10 (1.16-3.80) 0.01 1.75 (0.94-3.26) 0.08 1.30 (0.67-2.55) 0.44
Reduced serum HDL cholesterol 87 (8.1) 2.14 (0.93-4.94) 0.07 1.71 (0.71-4.08) 0.23 1.29 (0.51-3.25) 0.59
CI, confidence interval; HDL, high density lipoprotein.
The metabolic syndrome component was defined according to the Adult Treatment Panel III criteria (ATP III) criteria [6]. For further information, see methods.
aAdjusted for sex, age, body mass index, current smoking, current alcoholic intake and use of antihypertensive drugs (except for elevated blood pressure).
bAdditionally adjusted for the other components of metabolic syndrome.
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(odds ratio 2.05; P < 0.02) [10]. However, 2 other studies
demonstrated that microalbuminuria was associated
with all components of the metabolic syndrome [13,14],
probably because in these 2 studies the components of
the metabolic syndrome were not mutually adjusted.
Nonetheless, as exemplified in the present study, in sub-
jects without established cardiovascular disease, such as
treated hypertension might also be a significant correlate
of microalbuminuria.
The mechanism for the closer relationship of microalbu-
minuria with diastolic blood pressure and hyperglycemia is
not entirely understood. Microalbuminuria is a marker of
endothelial dysfunction and vascular damage [2,15]. The
metabolic syndrome is basically a disorder in the metabo-
lism of glucose and lipids [1]. However, recent studies sug-
gest that the metabolic syndrome can also be a disease in
arterioles [16]. Peripheral circulation is the major determi-
nant of diastolic blood pressure and glucose disposal.
Before type 2 diabetes mellitus or systolic hypertension is
developed, the metabolic syndrome is probably a vascular
disease in the periphery, which may cause mainly high dia-
stolic blood pressure and hyperglycemia.
Our study should be interpreted within the context of
its limitations. First, we only collected a random spot
urine sample. Though adjusting for urinary creatinine
excretion, the assessment of albumin excretion might be
less accurate than 24-hour urine collections or first
morning voids [17,18]. However, the spot urine sampling
also has advantages, such as rapid deep freezing after col-
lection, in the absence of any antiseptic agent. Second,
our study had a relatively small sample size. Only 46 per-
sons had microalbuminuria and 167 persons had the
metabolic syndrome. However, this shortfall might be
overcome by intensive and accurate measurement of all
the variables under study. Third, our study was cross-sec-
tional and hence no causal conclusion could be drawn.
In conclusion, microalbuminuria is common in the
Chinese population, and is much more prevalent in per-
sons with the metabolic syndrome, mainly attributable to
high diastolic blood pressure and high fasting plasma glu-
cose. Microalbuminuria is currently an indication of
interventions, such as blood pressure lowering [2], even
in the absence of hypertension or diabetes. However, the
metabolic syndrome is still considered as a controversial
and ambiguous phenomenon and by and large inade-
quately managed [19]. One of the important implications
of our study is that we probably should consider to
screen microalbuminuria in persons with prehyperten-
sion [20] or prediabetes [21], such as the blood pressure
and glucose components of the metabolic syndrome, and
to identify those at high cardiovascular risk but not on
any proven effective therapeutic treatment.
Acknowledgements
The authors gratefully acknowledge the voluntary participation of all study
subjects. The authors also appreciate the expert assistance of Shou-Yu Mao,
Jie Wang, Jun-Mei Xu, Li Zheng, and Wei-Zhong Zhang (The Shanghai
Institute of Hypertension, Shanghai, China). The study was financially
supported by grants from the National Natural Science Foundation of China
(30871360 and 30871081), the Ministry of Science and Technology
(2006BAI01A03) and the Ministry of Education (NCET-09-0544), Beijing, China,
the Shanghai Commissions of Science and Technology (07JC14047 and the
“Rising Star” program 06QA14043), Education (07ZZ32 and the “Dawn”
project 08SG20), the Shanghai Bureau of Health (2009111), the Shanghai
Shenkang Hospital Development Centre (SHDC12007318), Shanghai Jiaotong
University School of Medicine (a grant of Distinguished Young Investigators
to Yan Li), and the European Union (LSHM-CT-2006-037093 and HEALTH-F4-
2007-201550).
Authors’ contributions
CSS participated in the epidemiological and laboratory work, performed
statistical analysis, and together with JGW drafted the manuscript. BCH, WXF,
and JZ participated in the epidemiological work. YL and JGW conceived of,
designed and coordinated the study. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 25 October 2010 Accepted: 7 April 2011
Published: 7 April 2011
References
1. Lambers Heerspink HJ, Brinkman JW, Bakker SJ, Gansevoort RT, de Zeeuw D:
Update on microalbuminuria as a biomarker in renal and cardiovascular
disease. Curr Opin Nephrol Hypertens 2006, 15:631-6.
Table 4 Sensitivity analysis on the association between microalbuminuria and the metabolic syndrome or its
components
The metabolic syndrome component Number (Prevalence, %) Adjusted odds ratio (95% CI)* P value
Central obesity 248 (33.2) 1.53 (0.47-5.03) 0.48
Elevated blood pressure 193 (25.8) 2.20 (0.90-5.40) 0.08
Elevated fasting plasma glucose 66 (8.8) 2.30 (0.83-6.42) 0.11
Elevated serum triglycerides 210 (28.1) 1.65 (0.66-4.12) 0.48
Reduced serum HDL cholesterol 52 (7.0) 1.88 (0.54-6.50) 0.32
The metabolic syndrome 64 (8.6) 5.13 (1.96-13.45) 0.001
CI, confidence interval; HDL, high density lipoprotein.
* Adjusted for sex, age, body mass index, current smoking, current alcoholic intake and use of antihypertensive drugs (except for analyses on elevated blood
pressure and in subjects not taking antihypertensive medication) and additionally for the other components of the metabolic syndrome (except for analyses on
the metabolic syndrome).
Sheng et al. Diabetology & Metabolic Syndrome 2011, 3:6
http://www.dmsjournal.com/content/3/1/6
Page 5 of 62. Ochodnicky P, Henning RH, van Dokkum RP, de Zeeuw D:
Microalbuminuria and endothelial dysfunction: emerging targets for
primary prevention of end-organ damage. J Cardiovasc Pharmacol 2006,
47(Suppl 2):S151-62.
3. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Hallé JP,
Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S, HOPE Study Investigators:
Albuminuria and risk of cardiovascular events, death, and heart failure
in diabetic and nondiabetic individuals. JAMA 2001, 286:421-6.
4. Pan CY, Ho LT, Soegondo S, Prodjosudjadi W, Suwanwalaikorn S, Lim SC,
Chan TM, Chow KW, Thoenes M, Choi DS, DEMAND Study Investigators:
Prevalence of albuminuria and cardiovascular risk profile in a referred
cohort of patients with type 2 diabetes: an Asian perspective. Diabetes
Technol Ther 2008, 10:397-403.
5. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes
mellitus and its complications. Part 1: diagnosis and classification of
diabetes mellitus provisional report of a WHO consultation. Diabet Med
1998, 15:539-53.
6. National Cholesterol Education Program (NCEP): Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III). Third Report of the National
Cholesterol Education Program (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III) final report. Circulation 2002, 106:3143-421.
7. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA,
Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F:
American Heart Association; National Heart, Lung, and Blood Institute.
Diagnosis and management of the metabolic syndrome: An American
Heart Association/National Heart, Lung, and Blood Institute Scientific
Statement. Circulation 2005, 112:2735-52.
8. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA,
Fruchart JC, James WP, Loria CM, Smith SC Jr: International Diabetes
Federation Task Force on Epidemiology and Prevention; Hational Heart,
Lung, and Blood Institute; American Heart Association; World Heart
Federation; International Atherosclerosis Society; International
Association for the Study of Obesity. Harmonizing the metabolic
syndrome: a joint interim statement of the International Diabetes
Federation Task Force on Epidemiology and Prevention; National Heart,
Lung, and Blood Institute; American Heart Association; World Heart
Federation; International Atherosclerosis Society; and International
Association for the Study of Obesity. Circulation 2009, 120:1640-5.
9. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ: The metabolic syndrome.
Lancet 2010, 375:181-3.
10. Palaniappan L, Carnethon M, Fortmann SP: Association between
microalbuminuria and the metabolic syndrome: NHANES III. Am J
Hypertens 2003, 16:952-8.
11. Li Q, Jia WP, Lu JQ, Chen L, Wu YM, Jiang SY, Xiang KS: Relationship
between the prevalence of microalbuminuria and components of
metabolic syndrome in Shanghai. Chin J Epidemiol 2004, 25:65-88, in
Chinese.
12. Hao Z, Konta T, Takasaki S, Abiko H, Ishikawa M, Takahashi T, Ikeda A,
Ichikawa K, Kawata S, Kato T, Kubota I: The association between
microalbuminuria and metabolic syndrome in the general population in
Japan: the Takahata study. Intern Med 2007, 46:341-6.
13. Lin CC, Liu CS, Li TC, Chen CC, Li CI, Lin WY: Microalbuminuria and the
metabolic syndrome and its component s in the Chinese population. Eur
J Clin Invest 2007, 37:783-90.
14. Chen BD, Yang DG, Chen Y, Xu WY, Ye B, Ni ZY: The prevalence of
microalbuminuria and its relationships with the components of
metabolic syndrome in the general population of China. Chin Chim Acta
2010, 411:705-9.
15. de Zeeuw D, Parving HH, Henning RH: Microalbuminuria as an early
marker for cardiovascular disease. J Am Soc Nephrol 2006, 17:2100-5.
16. Levy BI, Schiffrin EL, Mourad JJ, Agostini D, Vicaut E, Safar ME, Struijker-
Boudier HA: Impaired tissue perfusion: a pathology common to
hypertension, obesity, and diabetes mellitus. Circulation 2008, 118:968-76.
17. Witte EC, Lambers Heerspink HJ, de Zeeuw D, Bakker SJ, de Jong PE,
Gansevoort R: First morning voids are more reliable than spot urine
samples to assess microalbuminuria. J Am Soc Nephrol 2009, 20:436-43.
18. Babazono T, Takahashi C, Iwamoto Y: Definition of microalbuminuria in
first-morning and random spot urine in diabetic patients. Diabetes Care
2004, 27:1838-9.
19. Simmons RK, Alberti KG, Gale EA, Colagiuri S, Tuomilehto J, Qiao Q,
Ramachandran A, Tajima N, Brajkovich Mirchov I, Ben-Nakhi A, Reaven G,
Hama Sambo B, Mendis S, Roglic G: The metabolic syndrome: useful
concept or clinical tool? Report of a WHO Expert Consultation.
Diabetologia 2010, 53:600-5.
20. Ogunniyi MO, Croft JB, Greenlund KJ, Giles WH, Mensah GA: Racial/ethnic
differences in microalbuminuria among adults with prehypertension and
hypertension: National Health and Nutrition Examination Survey
(NHANES), 1999-2006. Am J Hypertens 2010, 23:859-64.
21. Hwang ST, Cho YK, Yun JW, Park JH, Kim HJ, Park DI, Sohn CI, Jeon WK,
Kim BI, Rhee EJ, Oh KW, Lee WY, Jin W: Impact of non-alcoholic fatty liver
disease on microalbuminuria in patients with prediabetes and diabetes.
Intern Med J 2010, 40:437-42.
doi:10.1186/1758-5996-3-6
Cite this article as: Sheng et al.: Microalbuminuria in relation to the
metabolic syndrome and its components in a Chinese population.
Diabetology & Metabolic Syndrome 2011 3:6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Sheng et al. Diabetology & Metabolic Syndrome 2011, 3:6
http://www.dmsjournal.com/content/3/1/6
Page 6 of 6